384 related articles for article (PubMed ID: 34230110)
1. Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.
Ravirala D; Mistretta B; Gunaratne PH; Pei G; Zhao Z; Zhang X
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230110
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
3. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
4. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
[TBL] [Abstract][Full Text] [Related]
5. NK Cell Effector Functions and Bystander Tumor Cell Killing in Immunovirotherapy.
Floerchinger A; Engeland CE
Methods Mol Biol; 2022; 2521():233-248. PubMed ID: 35733001
[TBL] [Abstract][Full Text] [Related]
6. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
7. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
[TBL] [Abstract][Full Text] [Related]
8. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
[TBL] [Abstract][Full Text] [Related]
10. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing.
Ravirala D; Pei G; Zhao Z; Zhang X
Cancer Immunol Immunother; 2022 Jun; 71(6):1479-1495. PubMed ID: 34716463
[TBL] [Abstract][Full Text] [Related]
12. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic HSV as a vector in cancer immunotherapy.
Li H; Zhang X
Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
[TBL] [Abstract][Full Text] [Related]
14. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
15. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
16. Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells.
Fu X; Tao L; Wu W; Zhang X
Mol Ther Oncolytics; 2020 Dec; 19():33-46. PubMed ID: 33024817
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
18. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
19. Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers.
Song XT
Discov Med; 2013 Dec; 16(90):261-6. PubMed ID: 24333405
[TBL] [Abstract][Full Text] [Related]
20. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
Menotti L; Avitabile E
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
